4-氨基-3,4-二氢-2(1H)喹啉 | 858783-30-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氨基-3,4-二氢-2(1H)喹啉
• 英文名称: 4-Amino-3,4-dihydroquinolin-2(1H)-one
• 英文别名: 4-amino-3,4-dihydro-1H-quinolin-2-one
• CAS: 858783-30-9
• 化学式: C₉H₁₀N₂O
• mdl: MFCD09864321
• 分子量: 162.19
• InChiKey: DLABPBKCFXRHPA-UHFFFAOYSA-N

物化性质

• 沸点：
  339.9±42.0 °C(Predicted)
• 密度：
  1.189

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Spirohydantoin Aryl Cgrp Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20090239870A1

  公开（公告）日：2009-09-24

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , B, E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 and R 6 are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  公式I的化合物：（其中变量A1，A2，A3，A4，A5，A6，A7，B，E1，E2，E3，E4，E5，G1，G2和R6如本文所述），这些化合物是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物和组合物在预防或治疗CGRP参与的这些疾病中的应用。
• Spirolactam aryl cgrp receptor antagonists
  申请人：Bell Ian M.

  公开号：US20090247514A1

  公开（公告）日：2009-10-01

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 , J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  化学式为I的化合物：（其中变量A1、A2、A3、A4、A5、A6、A7、E1、E2、E3、E4、E5、G1、G2、J和K如本文所述）是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗CGRP参与的疾病的方法。
• Carboxamide Spirolactam Cgrp Receptor Antagonists
  申请人：Williams M. Theresa

  公开号：US20070293470A1

  公开（公告）日：2007-12-20

  The present invention is directed to compounds of Formula I: I (where variables A 1 , A 2 , B, J, K, m, n, R 4 , R 5a , R 5b and R 5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式I的化合物：I（其中变量A1、A2、B、J、K、m、n、R4、R5a、R5b和R5c如本文所定义），用作CGRP受体的拮抗剂，并用于治疗或预防涉及CGRP的疾病，例如头痛、偏头痛和群头痛。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及CGRP的疾病中的使用。
• 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US11053234B2

  公开（公告）日：2021-07-06

  A compound of formula (I) wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式 (I) 的化合物 其中 R、R1、R2、R3、Y、Y1、a、X 和 Z 如本文所定义。 本发明的化合物是造血前列腺素 D 合酶（H-PGDS）的抑制剂，可用于治疗杜氏肌肉萎缩症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物抑制 H-PGDS 活性和治疗相关疾病的方法。
• CARBOXAMIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1796678B1

  公开（公告）日：2010-04-14